Fu Shunlian, Zhou Qian, Gao Yang, Yang Yunjiao, Chen Huizhen, Yuan Lijun, Li Zinan, Chen Qiu
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Front Pharmacol. 2022 Aug 11;13:929169. doi: 10.3389/fphar.2022.929169. eCollection 2022.
Diabetic kidney disease (DKD) is a chronic progressive disorder which is a leading cause of chronic kidney disease (CKD). As an important pathogenesis of DKD, the overproduction of reactive oxygen species (ROS) and the inflammatory response have been considered central mediators in the progression of DKD. Herbal products are increasingly being applied as antioxidants and anti-inflammatory agents. Of those, the effect of hydroxyl safflower yellow A (HSYA) on oxidative stress and inflammatory reactions has gradually been investigated for DKD treatment, which may provide therapies for DKD with new insights and promote its application in clinical practice. We searched CNKI, the Chinese Biomedical Literature Database, the Wanfang Database, PubMed, and Embase from the establishment date of the database to 22 April 2022. The included literature in our study was randomized controlled trials (RCTs) using HSYA to treat DKD. We performed a meta-analysis by calculating the standard mean difference (SMD) with a 95% confidence interval (CI). The inverse-variance method with a random effect was used in our meta-analysis using Stata software and RevMan software. A total of 31 articles with 31 groups containing a total of 2487 participants were included in this meta-analysis. The pooled results showed a statistical improvement in the following measurements: fasting blood glucose (FBG), postprandial blood glucose (PBG), blood urea nitrogen (BUN), urinary albumin excretion rates (UAER), serum creatinine (SCR), hypersensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), fasting insulin (FINS), total cholesterol (TC), triglycerides (TGs), hemoglobin A1c (HbA1C), homeostasis model assessment insulin resistance (HOMA-IR), and malondialdehyde (MDA). HSYA can effectively treat DKD by inhibiting inflammatory reactions and oxidative stress, decreasing blood glucose and blood lipids, and improving renal function indices. However, more RCTs are still needed in the future to further demonstrate the effect of HSYA on biomarkers of oxidative stress and inflammatory reactions in patients with DKD due to the low quality and small sample size of the literature included in this study. PROSPERO: CRD 42021235689.
糖尿病肾病(DKD)是一种慢性进行性疾病,是慢性肾脏病(CKD)的主要病因。作为DKD的重要发病机制,活性氧(ROS)的过度产生和炎症反应被认为是DKD进展的核心介质。草药产品越来越多地被用作抗氧化剂和抗炎剂。其中,羟基红花黄色素A(HSYA)对氧化应激和炎症反应的作用已逐渐被研究用于DKD治疗,这可能为DKD提供新的治疗思路并促进其在临床实践中的应用。我们检索了中国知网、中国生物医学文献数据库、万方数据库、PubMed和Embase,检索时间从各数据库建库日期至2022年4月22日。我们研究纳入的文献为使用HSYA治疗DKD的随机对照试验(RCT)。我们通过计算标准均数差(SMD)及95%置信区间(CI)进行荟萃分析。我们使用Stata软件和RevMan软件,采用随机效应的逆方差法进行荟萃分析。本荟萃分析共纳入31篇文章,31组,共2487名参与者。汇总结果显示在以下测量指标上有统计学改善:空腹血糖(FBG)、餐后血糖(PBG)、血尿素氮(BUN)、尿白蛋白排泄率(UAER)、血清肌酐(SCR)、超敏C反应蛋白(hsCRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、空腹胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TGs)、糖化血红蛋白(HbA1C)、稳态模型评估胰岛素抵抗(HOMA-IR)和丙二醛(MDA)。HSYA可通过抑制炎症反应和氧化应激、降低血糖和血脂以及改善肾功能指标来有效治疗DKD。然而,由于本研究纳入文献质量较低且样本量较小,未来仍需要更多的RCT来进一步证明HSYA对DKD患者氧化应激和炎症反应生物标志物的影响。国际前瞻性系统评价注册库:CRD 42021235689。